Zhao Ruonan, Ma Lin, Wang Ruiping, Zhang Rongqiang
School of Public Health, Shaanxi University of Chinese Medicine, Xianyang, 712046, P. R. China.
Affiliated Hospital, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, P. R. China.
J Cardiothorac Surg. 2025 Jun 4;20(1):260. doi: 10.1186/s13019-025-03495-7.
The research focused on examining CpG methylation within the promoter area in chronic heart failure (CHF) patients, aiming to correlate methylation levels with clinical indexes to guide CHF treatment.
Whole blood samples from 20 CHF patients and 20 healthy controls were analyzed using MALDI-TOF-MS. Methylation levels of CpGs in the -FA42 region were compared between CHF patients, healthy controls, and CHF patients with varying cardiac functions.
-FA42_CpG_3 methylation was lower in CHF patients ( = 0.0407), while -FA42_CpG_8 was higher ( = 0.0183) compared to controls.
promoter methylation in CHF patients exhibited bidirectional regulation, potentially influencing coagulation, renal function, and blood routine. These results deepen understanding of CHF pathogenesis and suggest new treatment approaches.
本研究聚焦于检测慢性心力衰竭（CHF）患者启动子区域的CpG甲基化，旨在将甲基化水平与临床指标相关联，以指导CHF治疗。
使用基质辅助激光解吸电离飞行时间质谱（MALDI-TOF-MS）分析20例CHF患者和20例健康对照的全血样本。比较CHF患者、健康对照以及心功能不同的CHF患者中-FA42区域CpG的甲基化水平。
与对照组相比，CHF患者中-FA42_CpG_3甲基化水平较低（P = 0.0407），而-FA42_CpG_8甲基化水平较高（P = 0.0183）。
CHF患者启动子甲基化呈现双向调节，可能影响凝血、肾功能和血常规。这些结果加深了对CHF发病机制的理解，并提示了新的治疗方法。
